К содержанию
Dr. Tara EinullaevaMedical oncologist

Treatment 6 min

HER2-positive breast cancer: how targeted therapy works

What HER2-positive breast cancer means, which targeted drugs are used before and after surgery and for metastatic disease, and how the heart is monitored.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 19 October 2026

HER2-positive breast cancer is a tumor whose cells have too much HER2, a protein that drives growth. It used to be considered one of the least favorable types. Today, thanks to drugs that block HER2 precisely, treatment results have improved considerably: the key is to determine HER2 status accurately and to complete the full course of anti-HER2 therapy.

How HER2 is determined

HER2 is assessed by immunohistochemistry on a scale from 0 to 3+:

IHC result What it means
0 or 1+ HER2-negative tumor (1+ is HER2-low)
2+ borderline result, an ISH (FISH) test is needed
3+ HER2-positive tumor

If ISH shows HER2 gene amplification, the tumor is considered positive even with 2+ on IHC. According to the American Cancer Society, about 15–20% of breast cancers are HER2-positive. You can check your results in the IHC decoder.

Which drugs are used

There are three types of anti-HER2 drugs.

Monoclonal antibodies — block the HER2 receptor on the outside of the cell:

  • trastuzumab — intravenously or under the skin;
  • pertuzumab — together with trastuzumab and chemotherapy; there is also an under-the-skin combination of the two antibodies.

Antibody–drug conjugates — the antibody delivers chemotherapy directly to cells with HER2:

  • trastuzumab emtansine (T-DM1);
  • trastuzumab deruxtecan (T-DXd).

Tyrosine kinase inhibitors — tablets that block the signal inside the cell: tucatinib, neratinib, lapatinib.

HER2-positive and HER2-low are not the same

With the arrival of trastuzumab deruxtecan the concept of HER2-low appeared — tumors with HER2 1+ or 2+ without amplification on ISH. This isn’t HER2-positive cancer: standard anti-HER2 drugs (trastuzumab, pertuzumab) don’t work for it. But in metastatic disease, HER2-low status can open up the option of treatment with trastuzumab deruxtecan.

So in metastatic breast cancer it’s important to know not just “positive or negative” but the exact score: 0, 1+ or 2+. More in the article “IHC in breast cancer”.

How the drugs are given

Trastuzumab and pertuzumab can be given intravenously or under the skin — the American Cancer Society mentions subcutaneous forms, including a combination of both antibodies in one injection. An injection under the skin takes less time than an infusion. The choice of form depends on drug availability and the regimen — discuss it with your doctor.

Once chemotherapy is over, anti-HER2 therapy continues, and these visits are usually much easier: hair grows back, fatigue fades, and many people go back to work.

Early stages: before and after surgery

For a HER2-positive tumor, treatment often starts before surgery: chemotherapy plus trastuzumab and pertuzumab. As with other subtypes, this lets the doctor see how sensitive the tumor is — more in the article “Neoadjuvant and adjuvant therapy”.

What happens next depends on the result of surgery:

  • no tumor left — anti-HER2 therapy continues so that the total treatment adds up to a year;
  • tumor remains — according to the American Cancer Society, after surgery treatment switches to a conjugate: trastuzumab emtansine or trastuzumab deruxtecan.

After a year of trastuzumab, another year of neratinib tablets is considered in some cases.

For early-stage disease, anti-HER2 therapy is planned for a year. If treatment was interrupted because of side effects, discuss with your doctor whether it can be restarted — this directly affects the risk of the cancer coming back.

Metastatic disease

At stage 4, anti-HER2 therapy remains the basis; only the drugs change from line to line:

  • first line — chemotherapy with trastuzumab and pertuzumab; the American Cancer Society also mentions trastuzumab deruxtecan combined with pertuzumab;
  • after that — conjugates (trastuzumab deruxtecan, trastuzumab emtansine), tucatinib with trastuzumab and capecitabine, lapatinib.

If the tumor is also hormone-sensitive (ER+), hormone therapy is often added to treatment.

When a tumor is both HER2-positive and hormone-sensitive

Some HER2-positive tumors also have estrogen and/or progesterone receptors. Then treatment includes both: anti-HER2 therapy and hormone therapy. Hormone therapy usually starts after chemotherapy and continues for years — more in the article “Hormone therapy for breast cancer”.

Life during anti-HER2 therapy

A year of anti-HER2 therapy seems long, but most of it is maintenance infusions after chemotherapy has finished. What helps:

  • plan your visits — it’s convenient to mark the dates of infusions and heart checks in a calendar;
  • stay active — exercise is good for the heart too;
  • watch your blood pressure if you have hypertension — it’s a risk factor for heart complications;
  • don’t stop treatment without discussing it — if something makes it hard to continue, decide together with your doctor.

The heart during anti-HER2 therapy

The main specific risk of these drugs is reduced heart function. The American Cancer Society notes that it is usually temporary and improves after the drug is stopped, but it can sometimes lead to heart failure. The risk is higher:

  • if the regimen included anthracyclines (doxorubicin, epirubicin);
  • in patients over 50;
  • with excess weight, heart disease and high blood pressure.

That’s why heart function is checked before treatment and regularly during it — with an echocardiogram or a radionuclide scan (MUGA).

Tell your doctor if you develop breathlessness with ordinary activity, swollen legs, a racing heartbeat or a need to sleep propped up.

Pregnancy

Anti-HER2 drugs can harm an unborn baby. Reliable contraception is needed during treatment. If you are planning a pregnancy in the future, discuss it before treatment starts — including the possibility of fertility preservation.

Questions to ask your treating doctor

  • Has HER2 been confirmed by ISH if IHC was 2+?
  • Are we starting with drugs or with surgery?
  • How long will anti-HER2 therapy last in total?
  • How often will we check my heart?
  • What will we do if tumor remains after surgery?

If you want to make sure your plan follows current guidelines, I’ll go through your records at a consultation.

Sources

  1. Targeted Therapy for Breast Cancer — American Cancer Society
  2. Breast Cancer HER2 Status — American Cancer Society, 2026
  3. Recommendations for HER2 Testing in Breast Cancer: 2023 Update — College of American Pathologists / ASCO, 2023

Watch me explain this on video

Short videos on my Instagram (in Russian)

Frequently asked questions

This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.